Industry

Less rescue needed with Port Delivery System vs. photocoagulation

Healio Optometry3d ago1 min read

KIAWAH ISLAND, S.C. — In patients with proliferative diabetic retinopathy, ranibizumab delivered with the Port Delivery System yielded a reduced need for rescue intervention vs. panretinal photocoagulation, according to a presenter.At Kiawah Eye and Retina, Ford Gordon, MD, highlighted a clinical gap in research for the Port Delivery System (Genentech, PDS) as a treatment for proliferative diabetic retinopathy (PDR): While most previous studies have focused on PDS vs. anti-VEGF treatments for PDR, data guiding clinical decision-making between PDS and panretinal photocoagulation (PRP) is

Read full article on Healio Optometry

AI Summary

Quick Take

Data presented at the Kiawah Eye and Retina meeting indicates that the Port Delivery System (PDS) with ranibizumab reduces the need for rescue interventions in patients with proliferative diabetic retinopathy (PDR) compared to panretinal photocoagulation (PRP). This finding addresses a significant clinical research gap by providing a direct comparison between the continuous-delivery implant and the traditional laser gold standard.

Why It Matters

While panretinal photocoagulation is a mainstay for PDR, it is often associated with permanent peripheral vision loss and does not always provide the consistent VEGF suppression required to prevent disease progression. The PDS offers a surgical alternative to frequent anti-VEGF injections, but its utility compared to laser therapy has been less clear. These findings suggest that PDS may offer superior disease stability, potentially shifting the treatment paradigm for PDR patients who are at high risk for needing supplemental 'rescue' treatments.

Key Findings

Ranibizumab delivered via the Port Delivery System (PDS) yielded a reduced need for rescue intervention when compared directly to panretinal photocoagulation (PRP).
The study specifically addresses a clinical data gap, as most prior PDS research focused on comparisons with bolus anti-VEGF injections rather than laser therapy.
The findings suggest that continuous delivery of ranibizumab may provide more consistent control of proliferative diabetic retinopathy than traditional laser treatment.

Study Snapshot

Design

Clinical study comparison presented at Kiawah Eye and Retina

Population

Patients with proliferative diabetic retinopathy (PDR)

Practice Implications

Retina specialists should consider the PDS as a viable alternative for PDR patients who require long-term VEGF suppression but wish to avoid the side effects of PRP or the burden of frequent injections. The reduced need for rescue therapy suggests that PDS may offer a more predictable clinical course for high-risk diabetic patients.

Who's Affected

Retina SpecialistsOphthalmologistsPractice Owners

What's Next

As PDS continues to be integrated into PDR management, further data will likely be needed to define specific criteria for rescue interventions and to assess long-term visual field preservation compared to PRP.

Evidence StrengthPreliminary

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.